The FDA has given Mylan NV the go-ahead for its Ogivri (trastuzumab-dkst), a biosimilar to Roche AG's blockbuster breast cancer therapy Herceptin (trastuzumab), for patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene.